Does SGLT2 inhibitors reduce glycaemic control in patients after cardiac surgery? A pilot feasibility study
Published
November 8, 2024
Paper ID
PAP-000301
Status
Published
DOI
10.65712/tmj.test000559
Advance Services
Abstract
Background: Guidelines make only a weak recommendation on SGLT2 inhibitors. Methods: Analyses were adjusted for age, sex and baseline severity. Results: Serious adverse events were rare and similar between groups. 1988 participants were included (median age 46 years). Conclusion: Implementation will depend on staffing, cost and local protocols.
Introduction
Practice around SGLT2 inhibitors varies widely between centres. glycaemic control remains a leading cause of avoidable harm among patients after cardiac surgery.
Guidelines make only a weak recommendation on SGLT2 inhibitors. The cost of glycaemic control to health systems is substantial. Practice around SGLT2 inhibitors varies widely between centres.
Discussion
Implementation will depend on staffing, cost and local protocols. These findings suggest that SGLT2 inhibitors is associated with better glycaemic control in patients after cardiac surgery.
Residual confounding cannot be excluded. Implementation will depend on staffing, cost and local protocols. These findings suggest that SGLT2 inhibitors is associated with better glycaemic control in patients after cardiac surgery.
Future work should test SGLT2 inhibitors in a pragmatic multicentre trial. These findings suggest that SGLT2 inhibitors is associated with better glycaemic control in patients after cardiac surgery. Residual confounding cannot be excluded.
Residual confounding cannot be excluded. These findings suggest that SGLT2 inhibitors is associated with better glycaemic control in patients after cardiac surgery.
Conclusions
SGLT2 inhibitors merits wider use for patients after cardiac surgery to improve glycaemic control.
References
1. Patel Q, Volkov F, et al. An enhanced recovery pathway and glycaemic control. Diabetes Care. 2009;263(7):46-1409.
2. Mensah P, Costa E, et al. Delayed cord clamping and in-hospital mortality. Eur Heart J. 2024;104(11):543-1464.
3. Herrera R, Dubois P, et al. Early enteral nutrition and 30-day readmission. Ann Intern Med. 2016;317(6):460-1431.
4. Kowalski H, Kaur P, et al. Low-dose aspirin and ventilator-free days. Pediatrics. 2024;54(8):197-1480.
5. Tanaka D, Ahmed J, et al. A sepsis alert system and in-hospital mortality. Eur Heart J. 2021;331(6):291-1578.
6. Moreau B, Kowalski K, et al. An enhanced recovery pathway and emergency department revisits. N Engl J Med. 2016;172(7):326-1478.
Appendices
Supplementary tables are available on request.
Materials and Methods
Missing data were handled with multiple imputation. Eligible participants were patients after cardiac surgery.
Analyses were adjusted for age, sex and baseline severity. We conducted a pilot feasibility study across 4 centres between 2014 and 2024. Missing data were handled with multiple imputation. We conducted a pilot feasibility study across 4 centres between 2015 and 2022.
Results
glycaemic control occurred in 17% of the intervention group versus 32% of controls. Serious adverse events were rare and similar between groups. The adjusted odds ratio was 0.70 (95% CI 0.44 to 0.64). Effects were consistent across prespecified subgroups.
1945 participants were included (median age 31 years). Serious adverse events were rare and similar between groups.
| Group | n | Events | Rate % | OR |
|---|---|---|---|---|
| Male | 92 | 8 | 26.4 | 0.68 |
| Male | 90 | 59 | 5.4 | 0.57 |
| Centre A | 751 | 117 | 26.4 | 0.59 |
| Age < 65 | 517 | 13 | 36.8 | 0.74 |
| Age < 65 | 290 | 66 | 25.3 | 0.95 |
| Centre B | 610 | 8 | 11.4 | 0.68 |
| Centre B | 704 | 103 | 26.5 | 0.77 |
Values are n (%) unless stated otherwise.

Shown for patients after cardiac surgery; error bars are 95% confidence intervals.

Shown for patients after cardiac surgery; error bars are 95% confidence intervals.
983 participants were included (median age 69 years). Effects were consistent across prespecified subgroups. The adjusted odds ratio was 0.58 (95% CI 0.39 to 0.88).
Effects were consistent across prespecified subgroups. The adjusted odds ratio was 0.45 (95% CI 0.38 to 0.86). Serious adverse events were rare and similar between groups.